Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENCRT-103-hPI
- Development stage
- Unknown
- Lead developer
- Encellin
- Modality
- Cell Therapies
- Administration
- Implant, Subcutaneous
01
Overview
ENCRT-103-hPI is an investigational encapsulated cell replacement therapy (ENCRT) developed by Encellin, Inc. for the treatment of Type 1 Diabetes (T1D). The combination product consists of primary human islets (hPI) encapsulated within Encellin's proprietary ENC-103-CED implantable device. The ENC-103-CED is a soft, thin-film, pouch-like device made of non-fibrosis-inducing materials designed to physically shield the transplanted islets from the host's immune system, thereby preventing immune rejection and eliminating the need for chronic systemic immunosuppression. At the same time, the membrane allows for the exchange of oxygen, nutrients, and glucose-stimulated insulin secretion. ENCRT-103-hPI is entering Phase 1 clinical evaluation (NCT07680673) in Canada, supported by a partnership with Breakthrough T1D.
- Other names
- ENCRTmacro-encapsulated human primary islets
Beyond the preview
Go deeper on ENCRT-103-hPI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENCRT-103-hPI.